Natera, Inc. (NASDAQ:NTRA) Shares Acquired by LPL Financial LLC

LPL Financial LLC boosted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 33.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 80,332 shares of the medical research company's stock after purchasing an additional 20,260 shares during the quarter. LPL Financial LLC owned about 0.06% of Natera worth $12,717,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after purchasing an additional 166 shares during the period. EverSource Wealth Advisors LLC increased its position in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. raised its stake in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Remove Ads

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 25,931 shares of the company's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07. Following the completion of the transaction, the chief financial officer now owns 109,665 shares in the company, valued at approximately $18,091,435.05. This represents a 19.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at $1,366,129.12. This trade represents a 29.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock valued at $51,603,664 over the last three months. 7.60% of the stock is owned by corporate insiders.

Natera Stock Up 3.3 %

Natera stock traded up $4.39 during trading on Monday, reaching $138.26. The stock had a trading volume of 2,129,296 shares, compared to its average volume of 1,380,849. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The business has a 50 day moving average price of $156.27 and a 200 day moving average price of $151.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market cap of $18.69 billion, a PE ratio of -78.56 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Piper Sandler raised their price objective on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. Sanford C. Bernstein increased their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. Finally, The Goldman Sachs Group boosted their price target on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.